Hemodialysis Patient Fracture Risk and Medication Cohort Data

Patient cohort data from a medical claims database investigates fracture risk associated with secondary hyperparathyroidism medications in hemodialysis patients. The dataset includes 13,238 untreated patients, 4,847 vitamin D receptor activator users, and 5,977 calcimimetic users. The supplementary material was authored by figshare admin karger and last updated in April 2026.

Use Cases

• Compare fracture hospitalization hazard ratios between untreated, VDRA, and calcimimetic patient groups.
• Analyze the association between calcimimetic use and vertebral fracture risk using reported HRs and confidence intervals.
• Model hip fracture incidence risk based on patient treatment group assignment from the cohort study.
• Replicate the weighted Cox proportional hazards model with overlap weights for any fracture outcome.

Strengths

• Cohort includes 24,062 total patients from a large medical claims database.
• Provides hazard ratios with 95% confidence intervals for three distinct fracture outcomes.
• Clear patient stratification into three treatment groups for comparative analysis.

Limitations

• Dataset is very small (24.0 KB), likely containing only summary statistics, not individual patient records.
• Specific patient-level columns, demographics, and longitudinal data are unavailable.
• Geographic origin and exact time range of the claims data are not specified.

Provenance

Source

Large medical claims database (unspecified).

Collection Method

Retrospective cohort study using patient claims data.

Time Range

null

Freshness

null

Geography

null